Petrovax Pharm and FSUE St. Petersburg Research Institute of Vaccines and Sera (SPbRIVS) of the FMBA of Russia signed a
In the short term, the companies plan a joint
Within the framework of the agreement signed, Petrovax Pharm and SPbRIVS are also working on an ambitious investment project associated with the development and implementation of a quadrivalent
The companies aim at building up the international cooperation, i.e. extension of export potential of the existing and new products as well as joint participation in the immunobiological construction project development in Nicaragua.
«I am pleased with the fact that we are moving to a new level of cooperation with SPbRIVS. Our project aimed at creating an entirely local quadrivalent adjuvanted flu vaccine is a logical continuation of our R&D efforts that have provided for our success with Grippol vaccine," NPO Petrovax Pharm LLC Chairman of the Board Arkady Nekrasov commented upon signing the agreement.
«Our efforts on creating advanced local vaccines are in line with the government strategies, and are aimed at the implementation of the Federal Target Program
«I am sure that this partnership will be strategically important not only for our companies but also for the Russian pharma industry overall. This partnership will facilitate the development of research and production projects in the immunobiological industry, which is a strategic sector directly affecting the national security. We will be able to contribute to the development of Russia’s economy as well as present out manufacturing technologies and products on international markets,» emphasized SPbRIVS Director Victor Trukhin.